For pharmaceutical companies dedicated to producing critical medications like Rivastigmine, the meticulous selection of chemical intermediates is a cornerstone of their operation. 3-[1-(Dimethylamino)ethyl]phenol, bearing the CAS number 105601-04-5, is a prime example of such an essential compound. Its role as a key intermediate in Rivastigmine synthesis necessitates a focus on purity, consistency, and reliable availability. This article serves as a guide for procurement specialists and R&D teams looking to secure a stable supply of this vital pharmaceutical material.

The chemical properties of 3-[1-(Dimethylamino)ethyl]phenol are fundamental to its utility. With a molecular formula of C10H15NO and a molecular weight of 165.23 g/mol, it offers specific reactivity essential for complex organic synthesis. Manufacturers often specify its form as a pale brown solid with a melting point around 87-89°C. Understanding these physical and chemical characteristics is crucial for predicting its behavior in various reaction conditions and ensuring successful synthesis outcomes. When searching for 'CAS 105601-04-5 chemical properties', it's important to look for data from verified sources.

The global market for pharmaceutical intermediates is vast, with China emerging as a significant hub for manufacturing. For companies looking to 'buy 3-[1-(Dimethylamino)ethyl]phenol online', it is imperative to partner with reputable manufacturers and suppliers. Factors such as adherence to quality control standards, transparent documentation, and efficient logistics are critical. NINGBO INNO PHARMCHEM CO., LTD., as a manufacturer in China, offers a competitive advantage through its established infrastructure and expertise in producing high-purity chemical intermediates. Their commitment to quality makes them a reliable choice for consistent supply.

Choosing the right supplier for pharmaceutical intermediates like 3-[1-(Dimethylamino)ethyl]phenol is more than just a transactional decision; it's a strategic partnership. It impacts product quality, production timelines, and ultimately, patient safety. Pharmaceutical companies must conduct thorough due diligence to ensure their chosen partners meet rigorous industry standards. Investing in reliable sourcing from trusted pharmaceutical intermediate suppliers in China is an investment in the integrity and success of their finished products.